


**DARAPRIM - pyrimethamine tablet**  
**REMEDYREPACK INC.**

-----  
**DARAPRIM®(pyrimethamine)25-mg Scored Tablets**

**DESCRIPTION**

DARAPRIM (pyrimethamine) is an antiparasitic compound available in tablet form for oral administration. Each scored tablet contains 25 mg pyrimethamine and the inactive ingredients corn and potato starch, lactose, and magnesium stearate.

Pyrimethamine, known chemically as 5-(4-chlorophenyl)-6-ethyl-2,4-pyrimidinediamine, has the following structural formula:



$C_{12}H_{13}ClN_4$

Mol. Wt 248.71

**CLINICAL PHARMACOLOGY**

Pyrimethamine is well absorbed with peak levels occurring between 2 to 6 hours following administration. It is eliminated slowly and has a plasma half-life of approximately 96 hours. Pyrimethamine is 87% bound to human plasma proteins.

Pyrimethamine is a folic acid antagonist and the rationale for its therapeutic action is based on the differential requirement between host and parasite for nucleic acid precursors involved in growth. This activity is highly selective against plasmodia and *Toxoplasma gondii*.

Pyrimethamine possesses blood schizonticidal and some tissue schizonticidal activity against malaria parasites of humans. However, the 4-amino-quinoline compounds are more effective against the erythrocytic schizonts. It does not destroy gametocytes, but arrests sporogony in the mosquito.

The action of pyrimethamine against *Toxoplasma gondii* is greatly enhanced when used in conjunction with sulfonamides. This was demonstrated by Eyles and Coleman<sup>1</sup> in the treatment of experimental toxoplasmosis in the mouse. Jacobs et al<sup>2</sup> demonstrated that combination of the 2 drugs effectively prevented the development of severe uveitis in most rabbits following the inoculation of the anterior chamber of the eye with toxoplasma.

**INDICATIONS & USAGE**

DARAPRIM is indicated for the treatment of toxoplasmosis when used conjointly with a sulfonamide, since synergism exists with this combination.

DARAPRIM is also indicated for the treatment of acute malaria. It should not be used alone to treat acute malaria. Fast-acting schizonticides such as chloroquine or quinine are indicated and preferable for the treatment of acute malaria. However, conjoint use of DARAPRIM with a sulfonamide (e.g., sulfadoxine) will initiate transmission control and suppression of susceptible strains of plasmodia.

DARAPRIM is indicated for the chemoprophylaxis of malaria due to susceptible strains of plasmodia. However, resistance to pyrimethamine is prevalent worldwide. It is not suitable as a prophylactic agent for travelers to most areas.

## **CONTRAINDICATIONS**

Use of DARAPRIM is contraindicated in patients with known hypersensitivity to pyrimethamine or to any component of the formulation. Use of the drug is also contraindicated in patients with documented megaloblastic anemia due to folate deficiency.

## **WARNINGS**

The dosage of pyrimethamine required for the treatment of toxoplasmosis is 10 to 20 times the recommended antimalaria dosage and approaches the toxic level. If signs of folate deficiency develop (see **ADVERSE REACTIONS**), reduce the dosage or discontinue the drug according to the response of the patient. Folinic acid (leucovorin) should be administered in a dosage of 5 to 15 mg daily (orally, IV, or IM) until normal hematopoiesis is restored.

Data in 2 humans indicate that pyrimethamine may be carcinogenic: a 51-year-old female who developed chronic granulocytic leukemia after taking pyrimethamine for 2 years for toxoplasmosis,<sup>3</sup> and a 56-year-old patient who developed reticulum cell sarcoma after 14 months of pyrimethamine for toxoplasmosis.<sup>4</sup>

Pyrimethamine has been reported to produce a significant increase in the number of lung tumors in mice when given intraperitoneally at doses of 25 mg/kg.<sup>5</sup>

DARAPRIM should be kept out of the reach of infants and children as they are extremely susceptible to adverse effects from an overdose. Deaths in pediatric patients have been reported after accidental ingestion.

## **PRECAUTIONS**

The recommended dosage for chemoprophylaxis of malaria should not be exceeded. A small "starting" dose for toxoplasmosis is recommended in patients with convulsive disorders to avoid the potential nervous system toxicity of pyrimethamine. DARAPRIM should be used with caution in patients with impaired renal or hepatic function or in patients with possible folate deficiency, such as individuals with malabsorption syndrome, alcoholism, or pregnancy, and those receiving therapy, such as phenytoin, affecting folate levels (see **Pregnancy** subsection).

Patients should be warned that at the first appearance of a skin rash they should stop use of DARAPRIM and seek medical attention immediately. Patients should also be warned that the appearance of sore throat, pallor, purpura, or glossitis may be early indications of serious disorders which require

treatment with DARAPRIM to be stopped and medical treatment to be sought.

Women of childbearing potential who are taking DARAPRIM should be warned against becoming pregnant. Patients should be warned to keep DARAPRIM out of the reach of children. Patients should be advised not to exceed recommended doses. Patients should be warned that if anorexia and vomiting occur, they may be minimized by taking the drug with meals.

Concurrent administration of folic acid is strongly recommended when used for the treatment of toxoplasmosis in all patients.

In patients receiving high dosage, as for the treatment of toxoplasmosis, semiweekly blood counts, including platelet counts, should be performed.

Pyrimethamine may be used with sulfonamides, quinine and other antimalarials, and with other antibiotics. However, the concomitant use of other antifolate drugs or agents associated with myelosuppression including sulfonamides or trimethoprim-sulfamethoxazole combinations, proguanil, zidovudine, or cytostatic agents (e.g., methotrexate), while the patient is receiving pyrimethamine, may increase the risk of bone marrow suppression. If signs of folate deficiency develop, pyrimethamine should be discontinued. Folic acid (leucovorin) should be administered until normal hematopoiesis is restored (see **WARNINGS**). Mild hepatotoxicity has been reported in some patients when lorazepam and pyrimethamine were administered concomitantly.

See **WARNINGS** section for information on carcinogenesis.

**Mutagenesis:** Pyrimethamine has been shown to be nonmutagenic in the following *in vitro* assays: the Ames point mutation assay, the Rec assay, and the *E. coli* WP2 assay. It was positive in the L5178Y/TK +/- mouse lymphoma assay in the absence of exogenous metabolic activation.<sup>6</sup> Human blood lymphocytes cultured *in vitro* had structural chromosome aberrations induced by pyrimethamine.

*In vivo*, chromosomes analyzed from the bone marrow of rats dosed with pyrimethamine showed an increased number of structural and numerical aberrations.

**Teratogenic Effects:** Pregnancy Category C. Pyrimethamine has been shown to be teratogenic in rats when given in oral doses 7 times the human dose for chemoprophylaxis of malaria or 2.5 times the human dose for treatment of toxoplasmosis. At these doses in rats, there was a significant increase in abnormalities such as cleft palate, brachygnathia, oligodactyly, and microphthalmia. Pyrimethamine has also been shown to produce terata such as meningocele in hamsters and cleft palate in miniature pigs when given in oral doses 170 and 5 times the human dose, respectively, for chemoprophylaxis of malaria or for treatment of toxoplasmosis.

There are no adequate and well-controlled studies in pregnant women. DARAPRIM should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Concurrent administration of folic acid is strongly recommended when used for the treatment of toxoplasmosis during pregnancy.

Pyrimethamine is excreted in human milk. Because of the potential for serious adverse reactions in nursing infants from pyrimethamine and from concurrent use of a sulfonamide with DARAPRIM for treatment of some patients with toxoplasmosis, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother (see **WARNINGS** and **PRECAUTIONS: Pregnancy** ).

See **DOSAGE AND ADMINISTRATION** section.

Clinical studies of DARAPRIM did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

## **ADVERSE REACTIONS**

Hypersensitivity reactions, occasionally severe (such as Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, and anaphylaxis), and hyperphenylalaninemia, can occur particularly when pyrimethamine is administered concomitantly with a sulfonamide. Consult the complete prescribing information for the relevant sulfonamide for sulfonamide-associated adverse events. With doses of pyrimethamine used for the treatment of toxoplasmosis, anorexia and vomiting may occur. Vomiting may be minimized by giving the medication with meals; it usually disappears promptly upon reduction of dosage. Doses used in toxoplasmosis may produce megaloblastic anemia, leukopenia, thrombocytopenia, pancytopenia, atrophic glossitis, hematuria, and disorders of cardiac rhythm. Hematologic effects, however, may also occur at low doses in certain individuals (see **PRECAUTIONS: General**).

Pulmonary eosinophilia has been reported rarely.

## **OVERDOSAGE**

Following the ingestion of 300 mg or more of pyrimethamine, gastrointestinal and/or central nervous system signs may be present, including convulsions. The initial symptoms are usually gastrointestinal and may include abdominal pain, nausea, severe and repeated vomiting, possibly including hematemesis. Central nervous system toxicity may be manifest by initial excitability, generalized and prolonged convulsions which may be followed by respiratory depression, circulatory collapse, and death within a few hours. Neurological symptoms appear rapidly (30 minutes to 2 hours after drug ingestion), suggesting that in gross overdosage pyrimethamine has a direct toxic effect on the central nervous system.

The fatal dose is variable, with the smallest reported fatal single dose being 375 mg. There are, however, reports of pediatric patients who have recovered after taking 375 to 625 mg.

There is no specific antidote to acute pyrimethamine poisoning. In the event of overdosage, symptomatic and supportive measures should be employed. Gastric lavage is recommended and is effective if carried out very soon after drug ingestion. Parenteral diazepam may be used to control convulsions. Folinic acid should also be administered within 2 hours of drug ingestion to be most effective in counteracting the effects on the hematopoietic system (see **WARNINGS**). Due to the long half-life of pyrimethamine, daily monitoring of peripheral blood counts is recommended for up to several weeks after the overdose until normal hematologic values are restored.

## **DOSAGE & ADMINISTRATION**

The dosage of DARAPRIM for the treatment of toxoplasmosis must be carefully adjusted so as to

provide maximum therapeutic effect and a minimum of side effects. At the dosage required, there is a marked variation in the tolerance to the drug. Young patients may tolerate higher doses than older individuals. Concurrent administration of folic acid is strongly recommended in all patients.

The adult *starting* dose is 50 to 75 mg of the drug daily, together with 1 to 4 g daily of a sulfonamide of the sulfapyrimidine type, e.g., sulfadoxine. This dosage is ordinarily continued for 1 to 3 weeks, depending on the response of the patient and tolerance to therapy. The dosage may then be reduced to about one half that previously given for each drug and continued for an additional 4 to 5 weeks.

The pediatric dosage of DARAPRIM is 1 mg/kg/day divided into 2 equal daily doses; after 2 to 4 days this dose may be reduced to one half and continued for approximately 1 month. The usual pediatric sulfonamide dosage is used in conjunction with DARAPRIM.

DARAPRIM is NOT recommended alone in the treatment of acute malaria. Fast-acting schizonticides, such as chloroquine or quinine, are indicated for treatment of acute malaria. However, DARAPRIM at a dosage of 25 mg daily for 2 days with a sulfonamide will initiate transmission control and suppression of non-falciparum malaria. DARAPRIM is only recommended for patients infected in areas where susceptible plasmodia exist. Should circumstances arise wherein DARAPRIM must be used alone in semi-immune persons, the adult dosage for acute malaria is 50 mg for 2 days; children 4 through 10 years old may be given 25 mg daily for 2 days. In any event, clinical cure should be followed by the once-weekly regimen described below for chemoprophylaxis. Regimens which include suppression should be extended through any characteristic periods of early recrudescence and late relapse, i.e., for at least 10 weeks in each case.

Adults and pediatric patients over 10 years — 25 mg (1 tablet) once weekly

Children 4 through 10 years — 12.5 mg (1/2 tablet) once weekly

Infants and children under 4 years — 6.25 mg (1/4 tablet) once weekly

## HOW SUPPLIED

White, scored tablets containing 25 mg pyrimethamine, imprinted with “DARAPRIM” and “A3A” in bottles of 100 (NDC 52054-330-10)

**Store at 15° to 25°C (59° to 77°F) in a dry place and protect from light.**

## REFERENCES

1. Eyles DE, Coleman N. Synergistic effect of sulfadiazine and Daraprim against experimental toxoplasmosis in the mouse. *Antibiot Chemother.* 1953;3:483-490.
2. Jacobs L, Melton ML, Kaufman HE. Treatment of experimental ocular toxoplasmosis. *Arch Ophthalmol.* 1964;71:111-118.
3. Jim RTS, Elizaga FV. Development of chronic granulocytic leukemia in a patient treated with pyrimethamine. *Hawaii Med J.* 1977;36:173-176.
4. Sadoff L. Antimalarial drugs and Burkitt's lymphoma. *Lancet.* 1973;2:1262-1263.
5. Bahna L. Pyrimethamine. *LARC Monogr Eval Carcinog Risk Chem.* 1977;13:233-242.
6. Clive D, Johnson KO, Spector JKS, et al. Validation and characterization of the L5178Y/TK +/- mouse lymphoma mutagen assay

**PACKAGE LABEL.PRINCIPAL DISPLAY PANEL SECTION**

DRUG: DARAPRIM  
GENERIC: pyrimethamine  
DOSAGE: TABLET  
ADMINISTRATION: ORAL  
NDC: 52125-003-02  
STRENGTH: 25 mg  
COLOR: white  
SHAPE: ROUND  
SCORE: Two even pieces  
SIZE: 7 mm  
IMPRINT: 30  
QTY: 30



**DARAPRIM**

**25MG**  
**QTY:00030**

**NDC#: 52125-0003-02 INT:KD ID#:A3A**

**EXPIRES: 07/2013**

**LOT#: DP71212345**

**COL: white**

**SHP: round**

**DIST: AMEDRA PHARMA LLC MIDDLESEX NJ 08846**

**MFG: DSM PHARMA INC GREENVILLE NC 27834**

A. Caution Federal law prohibits transfer of this drug to any person other than for whom it was prescribed.

B. Store at a temperature between 15 degree C and 30 degree C (59 degree F and 86 degree F) {see USP}

C. Re-packaged by: RemedyRepack Inc. 655 Koltar Dr., Indiana, PA 15701, 1-724-465-8762





PHARMACY SERVICES

START

		16	8
	23	15	7
	22		6
	21		5
	20	12	4
	19	11	3
26	18	10	2
25	17	9	1
24			

# DARAPRIM

pyrimethamine tablet

## Product Information

<b>Product Type</b>	HUMAN PRESCRIPTION DRUG	<b>Item Code (Source)</b>	NDC:52125-003(NDC:52054-330)
<b>Route of Administration</b>	ORAL		

## Active Ingredient/Active Moiety

<b>Ingredient Name</b>	<b>Basis of Strength</b>	<b>Strength</b>
PYRIMETHAMINE (UNII: Z3614QOX8W) (PYRIMETHAMINE - UNII:Z3614QOX8W)	PYRIMETHAMINE	25 mg

## Inactive Ingredients

<b>Ingredient Name</b>	<b>Strength</b>
STARCH, CORN (UNII: O8232NY3SJ)	
STARCH, POTATO (UNII: 8I089SAH3T)	
LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)	
MAGNESIUM STEARATE (UNII: 70097M6I30)	

## Product Characteristics

<b>Color</b>	white	<b>Score</b>	2 pieces
<b>Shape</b>	ROUND (TABLET)	<b>Size</b>	7mm
<b>Flavor</b>		<b>Imprint Code</b>	DARAPRIM;A3A
<b>Contains</b>			

## Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:52125-003-02	30 in 1 BLISTER PACK		

## Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NDA	NDA008578	02/26/2013	

**Labeler** - REMEDYREPACK INC. (829572556)

Revised: 2/2013

REMEDYREPACK INC.